Fig. 1From: Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogressionChange in mean SUVmax from baseline to repeat GaTate PET/CT after SSA therapyBack to article page